---
layout: post
title: INNS for kinase inhibitors - January 2011
date: '2011-01-25T06:29:00.002Z'
author: John Overington
tags:
- INNS and USANS
- Kinase inhibitor
modified_time: '2011-08-28T12:14:32.912+01:00'
thumbnail: http://1.bp.blogspot.com/_SlPG9DIz_AA/TT5pgAYdwkI/AAAAAAAAA_Y/28LeRoGgZ54/s72-c/inns+and+usans.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7575303271383372223
blogger_orig_url: http://chembl.blogspot.com/2011/01/inns-for-kinase-inhibitors-january-2011.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://1.bp.blogspot.com/_SlPG9DIz_AA/TT5pgAYdwkI/AAAAAAAAA_Y/28LeRoGgZ54/s1600/inns+and+usans.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/_SlPG9DIz_AA/TT5pgAYdwkI/AAAAAAAAA_Y/28LeRoGgZ54/s1600/inns+and+usans.png" /></a></div><br />
<br />
There are two new kinase inhibitor INNs in the <a href="http://www.who.int/medicines/publications/druginformation/issues/PL-104.pdf">latest WHO list of proposed INNs</a>. (There are other kinase inhibitors in this document, but there are not new INNs/USANs - but if anyone knows anything about pacritinib I'd be glad to hear).<br />
<br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://1.bp.blogspot.com/_SlPG9DIz_AA/TT5pGfdfyeI/AAAAAAAAA_Q/WNi6nXfRhoQ/s1600/alisertib.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="168" src="http://1.bp.blogspot.com/_SlPG9DIz_AA/TT5pGfdfyeI/AAAAAAAAA_Q/WNi6nXfRhoQ/s320/alisertib.png" width="320" /></a></div><br />
<br />
<b>Alisertib</b> a.k.a. MLN-8237 - Millenium's Aurora kinase inhibitor, InChI key: APEDHRWNPCHTHU-UHFFFAOYSA-N InChI: InChI=1S/C27H19ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35) <a href="http://www.clinicaltrials.gov/ct2/results?flds=Xf&amp;flds=a&amp;flds=b&amp;term=MLN8237&amp;show_flds=Y">Phase 2</a><br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://3.bp.blogspot.com/_SlPG9DIz_AA/TT5pJtJqOgI/AAAAAAAAA_U/dh-2nlEmgtI/s1600/cenisertib.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="161" src="http://3.bp.blogspot.com/_SlPG9DIz_AA/TT5pJtJqOgI/AAAAAAAAA_U/dh-2nlEmgtI/s320/cenisertib.png" width="320" /></a></div><br />
<b>Cenisertib</b> a.k.a. AS-703569 and R-763 - Merck Serono's Aurora kinase inhibitor,&nbsp;InChI key:&nbsp;KSOVGRCOLZZTPF-QMKUDKLTSA-N&nbsp;InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1 <a href="http://clinicaltrials.gov/ct2/results?flds=Xf&amp;flds=a&amp;flds=b&amp;term=AS-703569&amp;show_flds=Y">Phase&nbsp;1</a>